Pathophysiology of thromboembolism in patients with COVID-19

Authors

  • Yethindra Vityala Department of Pathology, International Higher School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan https://orcid.org/0000-0003-1007-2422
  • Abhijit Krishna International Higher School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan
  • Dinesh Pandla International Higher School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan
  • Krishna Priya Kanteti Beihua University, Jilin, China
  • Jahnavi Sadhu Apollo College of Physiotherapy, Telangana, India
  • Harsha Vardhan Boddeti International Higher School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan
  • Tejesh Kintali International Higher School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan
  • Mohammad Shaour Khalid International Higher School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan

DOI:

https://doi.org/10.15584/ejcem.2022.2.10

Keywords:

acute respiratory distress syndrome, COVID-19, pathophysiology, pulmonary embolism, thromboembolism

Abstract

Introduction and aim. A small number of critically ill patients with coronavirus disease (COVID-19) develop thromboembolism (arterial or venous), both micro- and macrovascular complications such as deep vein thrombosis, pulmonary embolism, and pulmonary arterial thrombosis. The objective of the study is to describe the pathophysiology of venous thromboembolism in patients with COVID-19.

Material and methods. In this article a narrative review regarding pathophysiology of thromboembolism in patients with COVID-19.

Analysis of the literature. The development of coagulopathy is a consequence of the intense inflammatory response associated with hypercoagulability, platelet activation, and endothelial dysfunction. The pathophysiology that relates pulmonary thromboembolism (PTE) with COVID-19 is associated with a hypercoagulable state. PTE is suspected in hospitalized patients presenting dyspnea, decreased oxygen requirement, hemodynamic instability, and dissociation between hemodynamic and respiratory changes. In COVID-19-associated coagulopathy, initially, patients present with elevated levels of fibrinogen and D-dimer, with minimal changes in prothrombin time and platelet count. The main risk factor for the development of pulmonary embolism is the increase in D-dimer that is associated with the development of PTE. The administration of iodine-based contrast agent to patients with COVID-19 would affect P-creatinine and renal function, where Ultrasound is viewed as cost-effective and highly portable, can be performed at the bedside.

Conclusion. Acute respiratory distress syndrome severity in patients with COVID-19 can explain PTE as a consequence of an exaggerated immune response.

Downloads

Download data is not yet available.

References

Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest. 2020;50:e13209.

CDC. About COVID-19. Centers for Disease Control and Prevention; 2019. Available from: https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed: 2020 Dec 08.

WHO. Coronavirus. World Health Organization; 2019. Available from: https://www.who.int/health-topics/coronavirus. Accessed: 2021 Dec 08.

Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.

Gattinoni L, Pesenti A, Avalli L, Rossi F, Bombino M. Pressure-volume curve of total respiratory system in acute respiratory failure. Computed tomographic scan study. Am Rev Respir Dis. 1987;136(3):730-736.

Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135-1140.

Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-1009.

Espy MJ, Uhl JR, Sloan LM, et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev. 2006;19(1):165-256.

Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.

Corman VM, Müller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill. 2012;17(49):20334.

Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-1844.

Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368-370.

Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040.

Bertram S, Heurich A, Lavender H, et al. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS One. 2012;7(4):e35876.

Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.

Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136(10):1169-1179.

Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743-1746.

Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152-160.

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.

Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.

López-Reyes R, Oscullo G, Jiménez D, Cano I, García-Ortega A. Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach. Arch Bronconeumol. 2021;57:55-64.

Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128.

Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography. Radiology. 2020;296(3):186-188.

Mathews BK, Koenig S, Kurian L, et al. Clinical Progress Note: Point-of-Care Ultrasound Applications in COVID-19. J Hosp Med. 2020;15(6):353-355.

Lu W, Zhang S, Chen B et al. A Clinical Study of Noninvasive Assessment of Lung Lesions in Patients with Coronavirus Disease-19 (COVID-19) by Bedside Ultrasound. Ultraschall Med. 2020;41(03):300-307.

Gogna A, Yogendra P, Lee SHE, et al. Diagnostic ultrasound services during the coronavirus disease (COVID-19) pandemic. Am J Roentgenol. 2020;1-6.

Downloads

Published

2022-06-30

How to Cite

Vityala, Y., Krishna, A., Pandla, D., Priya Kanteti, K., Sadhu, J., Boddeti, H. V., Kintali, T., & Khalid, M. S. (2022). Pathophysiology of thromboembolism in patients with COVID-19. European Journal of Clinical and Experimental Medicine, 20(2), 212–216. https://doi.org/10.15584/ejcem.2022.2.10

Issue

Section

REVIEW PAPERS